Viking Therapeutics (1VT) Stock Forecast & Price Target

Compare

71 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1VT Analyst Ratings

Strong Buy

13 Buy

0 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Viking

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1VT Stock 12 Month Forecast

Average Price Target

€82.85

▲(188.27% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is €82.85 with a high forecast of €106.47 and a low forecast of €59.62. The average price target represents a 188.27% change from the last price of €28.74.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"€21","64":"€64","107":"€107","42.5":"€42.5","85.5":"€85.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":106.46624875,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€106.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":82.8477761273,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€82.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":59.6210993,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€59.62</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,42.5,64,85.5,107],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.6,38.28201913461539,43.96403826923077,49.64605740384616,55.328076538461545,61.01009567307693,66.69211480769232,72.37413394230771,78.0561530769231,83.73817221153848,89.42019134615387,95.10221048076924,100.78422961538462,{"y":106.46624875,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.6,36.46521354825385,40.33042709650769,44.19564064476154,48.06085419301539,51.92606774126923,55.79128128952308,59.65649483777692,63.52170838603077,67.38692193428462,71.25213548253845,75.1173490307923,78.98256257904615,{"y":82.8477761273,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32.6,34.6785461,36.7570922,38.8356383,40.914184399999996,42.9927305,45.0712766,47.1498227,49.2283688,51.306914899999995,53.385461,55.464007099999996,57.5425532,{"y":59.6210993,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":66.88,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.56,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.24,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.03,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.35,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.8,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.68,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.005,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.1,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.495,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.19,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€106.47

Average Price Target€82.85

Lowest Price Target€59.62

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Joseph Pantginis

H.C. Wainwright

€86.79

Buy

202.00%

Upside

Reiterated

12/18/25

Valuation and risks to price target achievement. We reiterate our Buy rating and $102 price target. Our valuation is based on contribution from all three clinical stage assets; VK2809, 28.2% contribution (80% chance of success); VK2735, 67.4% contribution (80% chance of success); and VK0214, 4.5% contribution (30% chance of success). Our price target is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug's potential commercial profile.

Andy Hsieh

William Blair

Buy

―

Reiterated

11/19/25

Promising Potential of Viking Therapeutics' VK2735 Justifies Buy Rating

Edward Nash

Canaccord Genuity

€90.2→€91.05

Buy

216.80%

Upside

Reiterated

11/11/25

Analysts' Top Healthcare Picks: Viking Therapeutics (VKTX), Privia Health Group (PRVA)

Biren Amin

Piper Sandler

€60.42

Buy

110.21%

Upside

Reiterated

11/10/25

Piper Sandler Remains a Buy on Viking Therapeutics (VKTX)

Naz Rahman

Maxim Group

€59.56

Buy

107.25%

Upside

Reiterated

11/07/25

Viking Therapeutics' VK2735: A Promising Step Forward in Metabolic Disease Treatment Justifying a Buy Rating

Justin Zelin

BTIG

€106.36

Buy

270.09%

Upside

Reiterated

10/30/25

Viking Therapeutics (VKTX) Gets a Buy from BTIG

Hardik Parikh

J.P. Morgan

€68.07→€63.82

Buy

122.06%

Upside

Reiterated

10/24/25

Viking Therapeutics price target lowered to $75 from $80 at JPMorganViking Therapeutics price target lowered to $75 from $80 at JPMorgan

Thomas Smith

Leerink Partners

€100.41

Buy

249.37%

Upside

Reiterated

10/23/25

Viking Therapeutics (VKTX) Receives a Rating Update from a Top Analyst

Joon Lee

Truist Financial

Buy

―

Reiterated

10/23/25

Viking Therapeutics (VKTX) Receives a Rating Update from a Top Analyst

Annabel Samimy

Stifel Nicolaus

€80.84

Buy

181.27%

Upside

Reiterated

10/23/25

Viking Therapeutics (VKTX) Gets a Buy from Stifel Nicolaus

Steven Seedhouse

Cantor Fitzgerald

€88.5→€89.35

Buy

210.88%

Upside

Reiterated

10/23/25

Viking Therapeutics offered 'transformative' Q3 update, says Cantor FitzgeraldViking Therapeutics offered 'transformative' Q3 update, says Cantor Fitzgerald

Michael Ulz

Morgan Stanley

€83.39→€86.79

Buy

202.00%

Upside

Reiterated

10/23/25

Promising Clinical Progress and Accelerated Enrollment Drive Buy Rating for Viking Therapeutics

Jay Olson

Oppenheimer

€85.09

Buy

196.08%

Upside

Reiterated

10/07/25

Analysts Offer Insights on Healthcare Companies: ClearPoint Neuro (NASDAQ: CLPT), BioLife Solutions (NASDAQ: BLFS) and Viking Therapeutics (NASDAQ: VKTX)

David Lebowitz

Citi

€32.33→€24.68

Hold

-14.14%

Downside

Reiterated

08/20/25

Viking Therapeutics (VKTX) Gets a Hold from Citi

Yale Jen

Laidlaw

€93.6

Buy

225.68%

Upside

Reiterated

08/20/25

Laidlaw Keeps Their Buy Rating on Viking Therapeutics (VKTX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Joseph Pantginis

H.C. Wainwright

€86.79

Buy

202.00%

Upside

Reiterated

12/18/25

Andy Hsieh

William Blair

Buy

―

Reiterated

11/19/25

Promising Potential of Viking Therapeutics' VK2735 Justifies Buy Rating

Edward Nash

Canaccord Genuity

€90.2→€91.05

Buy

216.80%

Upside

Reiterated

11/11/25

Analysts' Top Healthcare Picks: Viking Therapeutics (VKTX), Privia Health Group (PRVA)

Biren Amin

Piper Sandler

€60.42

Buy

110.21%

Upside

Reiterated

11/10/25

Piper Sandler Remains a Buy on Viking Therapeutics (VKTX)

Naz Rahman

Maxim Group

€59.56

Buy

107.25%

Upside

Reiterated

11/07/25

Viking Therapeutics' VK2735: A Promising Step Forward in Metabolic Disease Treatment Justifying a Buy Rating

Justin Zelin

BTIG

€106.36

Buy

270.09%

Upside

Reiterated

10/30/25

Viking Therapeutics (VKTX) Gets a Buy from BTIG

Hardik Parikh

J.P. Morgan

€68.07→€63.82

Buy

122.06%

Upside

Reiterated

10/24/25

Viking Therapeutics price target lowered to $75 from $80 at JPMorganViking Therapeutics price target lowered to $75 from $80 at JPMorgan

Thomas Smith

Leerink Partners

€100.41

Buy

249.37%

Upside

Reiterated

10/23/25

Viking Therapeutics (VKTX) Receives a Rating Update from a Top Analyst

Joon Lee

Truist Financial

Buy

―

Reiterated

10/23/25

Viking Therapeutics (VKTX) Receives a Rating Update from a Top Analyst

Annabel Samimy

Stifel Nicolaus

€80.84

Buy

181.27%

Upside

Reiterated

10/23/25

Viking Therapeutics (VKTX) Gets a Buy from Stifel Nicolaus

Steven Seedhouse

Cantor Fitzgerald

€88.5→€89.35

Buy

210.88%

Upside

Reiterated

10/23/25

Viking Therapeutics offered 'transformative' Q3 update, says Cantor FitzgeraldViking Therapeutics offered 'transformative' Q3 update, says Cantor Fitzgerald

Michael Ulz

Morgan Stanley

€83.39→€86.79

Buy

202.00%

Upside

Reiterated

10/23/25

Promising Clinical Progress and Accelerated Enrollment Drive Buy Rating for Viking Therapeutics

Jay Olson

Oppenheimer

€85.09

Buy

196.08%

Upside

Reiterated

10/07/25

Analysts Offer Insights on Healthcare Companies: ClearPoint Neuro (NASDAQ: CLPT), BioLife Solutions (NASDAQ: BLFS) and Viking Therapeutics (NASDAQ: VKTX)

David Lebowitz

Citi

€32.33→€24.68

Hold

-14.14%

Downside

Reiterated

08/20/25

Viking Therapeutics (VKTX) Gets a Hold from Citi

Yale Jen

Laidlaw

€93.6

Buy

225.68%

Upside

Reiterated

08/20/25

Laidlaw Keeps Their Buy Rating on Viking Therapeutics (VKTX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Viking Therapeutics

1 Month

xxx

Success Rate

14/22 ratings generated profit

Average Return

+12.39%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 63.64% of your transactions generating a profit, with an average return of +12.39% per trade.

3 Months

xxx

Success Rate

13/23 ratings generated profit

Average Return

+33.41%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 56.52% of your transactions generating a profit, with an average return of +33.41% per trade.

1 Year

Thomas SmithLeerink Partners

Success Rate

15/22 ratings generated profit

Average Return

+94.20%

reiterated a buy rating 2 months ago

Copying Thomas Smith's trades and holding each position for 1 Year would result in 68.18% of your transactions generating a profit, with an average return of +94.20% per trade.

2 Years

xxx

Success Rate

17/24 ratings generated profit

Average Return

+204.98%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 70.83% of your transactions generating a profit, with an average return of +204.98% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1VT Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1VT has received 25 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 1VT average Analyst price target in the past 3 months is 82.85.

Each month's total comprises the sum of three months' worth of ratings.

1VT Financial Forecast

1VT Earnings Forecast

Next quarter’s earnings estimate for 1VT is -€0.77 with a range of -€0.91 to -€0.67. The previous quarter’s EPS was -€0.69. 1VT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year 1VT has Performed in-line its overall industry.

No data currently available

1VT Sales Forecast

Next quarter’s sales forecast for 1VT is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 1VT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year 1VT has Performed in-line its overall industry.

1VT Stock Forecast FAQ

What is DE:1VT’s average 12-month price target, according to analysts?

Based on analyst ratings, Viking Therapeutics’s 12-month average price target is 82.85.

What is DE:1VT’s upside potential, based on the analysts’ average price target?

Viking Therapeutics has 188.27% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Viking Therapeutics a Buy, Sell or Hold?

Viking Therapeutics has a consensus rating of Strong Buy, which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.

What is Viking Therapeutics’s share price target?

The average share price target for Viking Therapeutics is 82.85. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €106.47 ,and the lowest forecast is €59.62. The average share price target represents 188.27% Increase from the current price of €28.74.

What do analysts say about Viking Therapeutics?

Viking Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of Viking Therapeutics?

To buy shares of DE:1VT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Viking Therapeutics (1VT) Stock Forecast & Price Target

1VT Analyst Ratings

1VT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Viking Therapeutics

1VT Analyst Recommendation Trends

1VT Financial Forecast

1VT Earnings Forecast

1VT Sales Forecast

1VT Stock Forecast FAQ

Detailed List of Analyst Forecasts